Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A

INTRODUCTION: Emicizumab promotes effective haemostasis in people with haemophilia A (PwHA). It is indicated for routine prophylaxis of bleeding episodes in PwHA with or without factor (F)VIII inhibitors. AIM: To investigate the effect of emicizumab dose up‐titration in PwHA with suboptimal bleeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Christophe, Mancuso, Maria Elisa, Chang, Tiffany, Podolak‐Dawidziak, Maria, Petry, Claire, Sidonio Jr, Robert, Yoneyama, Koichiro, Key, Nigel S., Niggli, Markus, Lehle, Michaela, Peyvandi, Flora, Oldenburg, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091821/
https://www.ncbi.nlm.nih.gov/pubmed/36271487
http://dx.doi.org/10.1111/hae.14679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091821/
https://www.ncbi.nlm.nih.gov/pubmed/36271487
http://dx.doi.org/10.1111/hae.14679

Ejemplares similares